UNLEASH
Harnessing the splicing code for targeted control of gene expression
Principal Investigator/s
Field / Programme
Genome Biology
Genome Biology
Summary
Alternative splicing (AS) is the important process allowing the production of different messenger RNAs and proteins from a single gene in complex organisms, including humans. AS alterations contribute to diseases such as cancer and neurodegeneration. While AS-targeting drugs have recently provided the first therapy for a common genetic disorder, much remains to be learnt about the mechanisms controlling splicing and their modulation by small molecules. Funded by the European Research Council, the multidisciplinary UNLEASH project aims to understand how splice site selection is regulated and whether it can be specifically modulated by small molecules. The project will generate many new tool compounds to study gene function and potentially help develop new therapeutics
Alternative splicing (AS) is the important process allowing the production of different messenger RNAs and proteins from a single gene in complex organisms, including humans. AS alterations contribute to diseases such as cancer and neurodegeneration. While AS-targeting drugs have recently provided the first therapy for a common genetic disorder, much remains to be learnt about the mechanisms controlling splicing and their modulation by small molecules. Funded by the European Research Council, the multidisciplinary UNLEASH project aims to understand how splice site selection is regulated and whether it can be specifically modulated by small molecules. The project will generate many new tool compounds to study gene function and potentially help develop new therapeutics
Start: 01/06/2023 End: 31/05/2029
Total Budget: 5.000.764,00
CRG Budget: 2.500.764,00
Funded by:
